Document Detail

How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
MedLine Citation:
PMID:  20613629     Owner:  NLM     Status:  MEDLINE    
An increasing number of patients in the community are being treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers for hypertension, coronary disease or diabetic renal and vascular complications. Some of these patients will develop heart failure despite such treatment. Based on data from hypertension trials it can be estimated that approximately 5% of treated patients will develop heart failure over 5 years. It is unclear whether patients developing heart failure on and off ACE-inhibitors or beta-blockers, respectively, at the time of heart failure diagnosis have similar prognosis.Treatment options for patients developing heart failure while already treated with ACE inhibitors/ARBs and beta-blockers are very limited if current heart failure guidelines are followed. In this review possible strategies are outlined and important areas for research are identified. It is suggested that trials are designed specifically to address prognosis and treatment in this growing population.
Finn Gustafsson; Julian Segura; Luis M Ruilope
Related Documents :
22343799 - Candesartan improves impaired endothelial function in the human coronary artery.
22452829 - Percutaneous treatment of patients with heart diseases: selection, guidance and follow-...
1978979 - Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and...
22423149 - Multidirectional left ventricular performance detected with three-dimensional speckle-t...
10999979 - Are we inhibited? renal insufficiency should not preclude the use of ace inhibitors for...
21705999 - Optimal role of rest and stress echocardiography in cardiac resynchronization therapy.
15073709 - Comparison of esophageal doppler, pulse contour analysis, and real-time pulmonary arter...
17418289 - Randomized early versus late abciximab in acute myocardial infarction treated with prim...
17470209 - Primary extracorporeal membrane oxygenation versus primary ventricular assist device im...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of hypertension     Volume:  28     ISSN:  1473-5598     ISO Abbreviation:  J. Hypertens.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-21     Completed Date:  2010-11-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  1595-8     Citation Subset:  IM    
Department of Cardiology, University of Copenhagen, Denmark bHypertension Unit, Hospital 12 de Octubre, Rigshospitalet, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Coronary Artery Disease / complications,  diagnosis,  drug therapy*
Diabetes Complications / diagnosis,  prevention & control*
Disease Progression
Heart Failure / etiology,  prevention & control*
Hypertension / complications,  diagnosis,  drug therapy*
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experiment...
Next Document:  Neuroretinitis with retrobulbar involvement.